Stocks and Investing Stocks and Investing
Fri, September 14, 2018
Thu, September 13, 2018

Paul Matteis Maintained (ALNY) at Strong Buy with Decreased Target to $117 on, Sep 13th, 2018


Published on 2024-10-26 08:40:42 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Decreased Target from $123 to $117 on, Sep 13th, 2018.

Paul has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $93 on, Monday, August 13th, 2018


These are the ratings of the 5 analyists that currently disagree with Paul


  • Christopher Marai of "Nomura" Maintained at Sell with Decreased Target to $73 on, Monday, August 13th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $125 on, Monday, August 13th, 2018
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $230 on, Monday, August 13th, 2018
  • Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $147 on, Monday, August 13th, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $123 on, Monday, August 13th, 2018
Contributing Sources